Foghorn Therapeutics Inc. current report, 19 May 2022

Full document

Foghorn Therapeutics Inc. — Form 8-K Summary

Business Context and Reporting Period

Foghorn Therapeutics Inc. filed a Current Report on Form 8-K dated May 19, 2022. The filing furnished an investor presentation and reported an FDA regulatory action involving the company’s FHD-286 clinical program.

Key Financial Metrics

This Form 8-K does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial metrics.

Material Changes Versus the Prior Comparable Period

  • The FDA placed the Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome on a partial clinical hold.
  • The hold followed a recent subject death involving potential differentiation syndrome, an adverse event associated with therapies that induce differentiation and believed to be related to FHD-286’s proposed mechanism of action.

Guidance, Outlook, Risks, and Unusual Items

  • The FDA requested a review of the safety database, risk-mitigation strategies, and clinical activity by dose level.
  • Foghorn suspended guidance regarding the timing of data release for the FHD-286 dose-escalation program until the partial clinical hold is resolved.
  • The hold may delay clinical development and data disclosure and could require additional safety measures or changes to the study. The filing does not provide a specific resolution timetable.
  • The investor presentation was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.

Investor Verification Checklist

  • Verify the FDA’s requested safety analyses and any subsequent resolution or modification of the partial clinical hold.
  • Assess the reported death, potential differentiation syndrome, and related risk-mitigation requirements.
  • Confirm revised timing for FHD-286 dose-escalation data and any changes to the clinical development plan.
  • Review the May 2022 investor presentation and press release furnished as Exhibits 99.1 and 99.2.
  • Review later filings for financial condition, liquidity, funding needs, and additional clinical or regulatory developments, which are not provided in this filing.